Eliem Therapeutics Comprehensive Income 2021-2024 | CLYM
Eliem Therapeutics comprehensive income from 2021 to 2024. Comprehensive income can be defined as the change in net assets of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
Eliem Therapeutics Annual Comprehensive Income
(Millions of US $) |
| 2023 |
$-0 |
| 2022 |
$-0 |
| 2021 |
$-0 |
| 2020 |
$ |
Eliem Therapeutics Quarterly Comprehensive Income
(Millions of US $) |
| 2024-06-30 |
|
| 2024-03-31 |
|
| 2023-12-31 |
$-0 |
| 2023-09-30 |
$-0 |
| 2023-06-30 |
$-0 |
| 2023-03-31 |
$-0 |
| 2022-12-31 |
$-0 |
| 2022-09-30 |
$-1 |
| 2022-06-30 |
$-1 |
| 2022-03-31 |
$-1 |
| 2021-12-31 |
$-0 |
| 2021-09-30 |
$-0 |
| 2021-06-30 |
|
| 2021-03-31 |
|
| 2020-12-31 |
|
| 2020-09-30 |
|
| 2020-06-30 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$0.346B |
$0.000B |
|
Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based in SEATTLE, United Kingdom.
|
